Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
Authors
Keywords
-
Journal
Scientific Reports
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-04-24
DOI
10.1038/srep04782
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents
- (2015) Thomas Reiner et al. NEOPLASIA
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis
- (2013) Cheryl Eifert et al. GENES CHROMOSOMES & CANCER
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry
- (2013) B. M. Zeglis et al. JOURNAL OF NUCLEAR MEDICINE
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
- (2013) Munevver Cinar et al. LEUKEMIA RESEARCH
- 89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges
- (2013) Gabriel Fischer et al. MOLECULES
- Metrics other than potency reveal systematic variation in responses to cancer drugs
- (2013) Mohammad Fallahi-Sichani et al. Nature Chemical Biology
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo
- (2013) Greg M. Thurber et al. Nature Communications
- Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
- (2013) Karin Strijbis et al. PLoS Pathogens
- Development of a Novel Long-Lived ImmunoPET Tracer for Monitoring Lymphoma Therapy in a Humanized Transgenic Mouse Model
- (2012) Arutselvan Natarajan et al. BIOCONJUGATE CHEMISTRY
- Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
- (2012) Y.-T. Tai et al. BLOOD
- Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma
- (2012) A. M. Bogusz et al. CLINICAL CANCER RESEARCH
- Bruton's Tyrosine Kinase Regulates Shigella flexneri Dissemination in HT-29 Intestinal Cells
- (2012) Ana-Maria Dragoi et al. INFECTION AND IMMUNITY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies
- (2012) Yan Lou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Regulation of Nucleocytoplasmic Shuttling of Bruton's Tyrosine Kinase (Btk) through a Novel SH3-Dependent Interaction with Ankyrin Repeat Domain 54 (ANKRD54)
- (2012) M. O. Gustafsson et al. MOLECULAR AND CELLULAR BIOLOGY
- From drug discovery to biomarker-driven clinical trials in lymphoma
- (2012) Anas Younes et al. Nature Reviews Clinical Oncology
- Synthesis and In Vivo Imaging of a 18F-Labeled PARP1 Inhibitor Using a Chemically Orthogonal Scavenger-Assisted High-Performance Method
- (2011) Thomas Reiner et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- 89Zr-Labeled Dextran Nanoparticles Allow in Vivo Macrophage Imaging
- (2011) Edmund J. Keliher et al. BIOCONJUGATE CHEMISTRY
- Analysis of Mitosis and Antimitotic Drug Responses in Tumors by In Vivo Microscopy and Single-Cell Pharmacodynamics
- (2011) J. D. Orth et al. CANCER RESEARCH
- Intravital Imaging
- (2011) Mikael J. Pittet et al. CELL
- High-Yielding, Two-Step18F Labeling Strategy for18F-PARP1 Inhibitors
- (2011) Edmund J. Keliher et al. ChemMedChem
- B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia
- (2010) H. M. Kerns et al. BLOOD
- 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
- (2010) J. P. Holland et al. JOURNAL OF NUCLEAR MEDICINE
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients
- (2009) P. K.E. Borjesson et al. JOURNAL OF NUCLEAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started